NASDAQ:GDRX GoodRx (GDRX) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free GDRX Stock Alerts $7.48 -0.58 (-7.20%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$7.45▼$8.4650-Day Range$6.50▼$8.0652-Week Range$4.14▼$9.37Volume2.53 million shsAverage Volume1.50 million shsMarket Capitalization$2.81 billionP/E RatioN/ADividend YieldN/APrice Target$8.95 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get GoodRx alerts: Email Address GoodRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside19.6% Upside$8.95 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 26 Articles This WeekInsider TradingN/AProj. Earnings Growth34.78%From $0.23 to $0.31 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.79 out of 5 starsMedical Sector422nd out of 918 stocksData Processing & Preparation Industry28th out of 57 stocks 3.3 Analyst's Opinion Consensus RatingGoodRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 11 buy ratings, 8 hold ratings, and 1 sell rating.Amount of Analyst CoverageGoodRx has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GoodRx's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GDRX. Previous Next 0.0 Dividend Strength Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GDRX. Previous Next 2.9 News and Social Media Coverage News SentimentGoodRx has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for GoodRx this week, compared to 5 articles on an average week.Search Interest16 people have searched for GDRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added GoodRx to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.37% of the stock of GoodRx is held by insiders.Percentage Held by Institutions63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GoodRx's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for GoodRx are expected to grow by 34.78% in the coming year, from $0.23 to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is -747.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is -747.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioGoodRx has a PEG Ratio of 3.28. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 4.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GoodRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About GoodRx Stock (NASDAQ:GDRX)GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.Read More GDRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GDRX Stock News HeadlinesApril 22, 2024 | marketbeat.comWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.April 22, 2024 | marketbeat.comWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (GDRX)The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolioMay 18 at 5:44 AM | americanbankingnews.comGoodRx (NASDAQ:GDRX) PT Raised to $16.00 at TD CowenMay 18 at 4:16 AM | americanbankingnews.comRaymond James Upgrades GoodRx (NASDAQ:GDRX) to "Outperform"May 17 at 12:15 PM | msn.comRaymond James Upgrades GoodRx Holdings (GDRX)May 17 at 1:54 AM | americanbankingnews.comGoodRx (NASDAQ:GDRX) Shares Gap Up Following Analyst UpgradeMay 16 at 5:35 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against GoodRx Holdings, Inc. - GDRXMay 16 at 5:32 PM | businesswire.comKirby McInerney LLP Reminds GoodRx Holdings, Inc. (GDRX) Investors of Class Action Filing and Encourages Investors to Contact the FirmMay 16 at 11:11 AM | markets.businessinsider.comKeyBanc Remains a Buy on GoodRx Holdings (GDRX)May 16 at 11:11 AM | msn.comGoodRx Holdings, Seelos Therapeutics, Clever Leaves among healthcare moversMay 15 at 6:59 PM | prnewswire.comGoodRx Holdings, Inc. (GDRX) Investors: June 21, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPMay 15 at 12:45 PM | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the FirmMay 15 at 6:00 AM | businesswire.comGoodRx and Kroger Sign Direct Contracting AgreementMay 15 at 5:45 AM | prnewswire.comGoodRx Holdings, Inc. Class Action: Levi & Korsinsky Reminds GoodRx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 21, 2024 - GDRXMay 14, 2024 | prnewswire.comGDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud LawsuitMay 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Barinthus Biotherapeutics (BRNS) and GoodRx Holdings (GDRX)May 14, 2024 | prnewswire.comThe Gross Law Firm Notifies Shareholders of GoodRx Holdings, Inc.(GDRX) of a Class Action Lawsuit and an Upcoming DeadlineMay 13, 2024 | prnewswire.comROSEN, NATIONAL TRIAL LAWYERS, Encourages GoodRx Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GDRXMay 13, 2024 | prnewswire.comLevi & Korsinsky Notifies Shareholders of GoodRx Holdings, Inc.(GDRX) of a Class Action Lawsuit and an Upcoming DeadlineMay 12, 2024 | markets.businessinsider.comMaintaining Hold: GoodRx’s Steady Performance and Upcoming Investor Day InsightsMay 12, 2024 | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxMay 11, 2024 | prnewswire.comGoodRx Holdings, Inc. (GDRX) Investors: June 21, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPMay 11, 2024 | americanbankingnews.comGoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from AnalystsMay 10, 2024 | prnewswire.comGDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud LawsuitMay 10, 2024 | finance.yahoo.comGoodRx Holdings Inc (GDRX) Q1 2024 Earnings: Navigates Market Challenges with Strategic AdjustmentsSee More Headlines Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/18/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Data processing & preparation Sub-IndustryN/A Current SymbolNASDAQ:GDRX CUSIPN/A CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees694Year FoundedN/APrice Target and Rating Average Stock Price Target$8.95 High Stock Price Target$16.00 Low Stock Price Target$4.50 Potential Upside/Downside+19.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio32.52 P/E Growth3.28Net Income$-8,870,000.00 Net Margins-0.86% Pretax Margin-7.70% Return on Equity3.45% Return on Assets1.70% Debt Debt-to-Equity Ratio1.02 Current Ratio6.29 Quick Ratio6.29 Sales & Book Value Annual Sales$750.27 million Price / Sales3.74 Cash Flow$0.38 per share Price / Cash Flow19.52 Book Value$1.68 per share Price / Book4.45Miscellaneous Outstanding Shares375,200,000Free Float370,065,000Market Cap$2.81 billion OptionableOptionable Beta1.37 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Trevor Bezdek (Age 46)Co-founder & Chairman Comp: $537kMr. Douglas Joseph Hirsch (Age 53)Co-founder, Chief Mission Officer & Director Comp: $507.29kMr. Karsten Ian Voermann (Age 54)CFO & Principal Financial Officer Comp: $693.69kMr. Romin Nabiey (Age 36)Chief Accounting Officer & Principal Accounting Officer Comp: $516kMr. Scott W. Wagner (Age 53)Interim CEO & Principal Operating Officer Mr. Mike WalshPresident & Executive VP of Prescription MarketplaceMs. Whitney NotaroVice President of Investor RelationsMs. Gracye ChengGeneral Counsel & SecretaryMr. Andrew Slutsky (Age 37)Chief Marketing Officer Comp: $864.8kMs. Vina M. Leite (Age 54)Chief People Officer More ExecutivesKey CompetitorsMerusNASDAQ:MRUSProgynyNASDAQ:PGNYCertaraNASDAQ:CERTBausch Health CompaniesNYSE:BHCInari MedicalNASDAQ:NARIView All CompetitorsInsiders & InstitutionsWalleye Trading LLCSold 21,800 shares on 5/17/2024Ownership: 0.000%Beacon Capital Management LLCBought 4,000 shares on 5/17/2024Ownership: 0.001%California State Teachers Retirement SystemBought 3,444 shares on 5/16/2024Ownership: 0.018%Bayesian Capital Management LPSold 27,100 shares on 5/16/2024Ownership: 0.004%EntryPoint Capital LLCBought 11,548 shares on 5/14/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions GDRX Stock Analysis - Frequently Asked Questions Should I buy or sell GoodRx stock right now? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GDRX shares. View GDRX analyst ratings or view top-rated stocks. What is GoodRx's stock price target for 2024? 20 analysts have issued 1 year price targets for GoodRx's shares. Their GDRX share price targets range from $4.50 to $16.00. On average, they expect the company's stock price to reach $8.95 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price. View analysts price targets for GDRX or view top-rated stocks among Wall Street analysts. How have GDRX shares performed in 2024? GoodRx's stock was trading at $6.70 on January 1st, 2024. Since then, GDRX stock has increased by 11.6% and is now trading at $7.48. View the best growth stocks for 2024 here. When is GoodRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our GDRX earnings forecast. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) issued its quarterly earnings results on Thursday, February, 29th. The company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. The company had revenue of $196.64 million for the quarter, compared to analysts' expectations of $195.59 million. GoodRx had a positive trailing twelve-month return on equity of 3.45% and a negative net margin of 0.86%. What ETFs hold GoodRx's stock? ETFs with the largest weight of GoodRx (NASDAQ:GDRX) stock in their portfolio include WisdomTree Growth Leaders Fund (PLAT), Global X Telemedicine & Digital Health ETF (EDOC) and Fidelity Digital Health ETF (FDHT).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has GoodRx issued on next quarter's earnings? GoodRx updated its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $800.0 million-$810.0 million, compared to the consensus revenue estimate of $801.0 million. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX). When did GoodRx IPO? GoodRx (GDRX) raised $900 million in an IPO on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. Who are GoodRx's major shareholders? GoodRx's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.05%), Assenagon Asset Management S.A. (0.26%), Picton Mahoney Asset Management (0.12%), GSA Capital Partners LLP (0.06%), Susquehanna Portfolio Strategies LLC (0.05%) and Mirae Asset Global Investments Co. Ltd. (0.05%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Lake Group LLC Silver, Scott Wagner and Trevor Bezdek. View institutional ownership trends. How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GDRX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
